NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DA-25-010 from the NIH Guide for Grants and Contracts. The Notice of Funding Opportunity (NOFO) aims to support research addressing the interplay of autophagy orchestrated cell death and HIV pathogenesis with a focus on the CNS cellular immune responses influenced by acute and chronic drug use.
Funding Opportunity RFA-DA-25-009 from the NIH Guide for Grants and Contracts. The Notice of Funding Opportunity (NOFO) aims to address the interplay of autophagy orchestrated cell death and HIV pathogenesis with a focus on the CNS cellular immune responses influenced by acute and chronic drug use.
Funding Opportunity RFA-CA-24-021 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) soliciting UG3/UH3 applications for the pediatric arm of the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The overall goal of the NOFO is to advance new cell therapy strategies into clinical testing for the treatment of solid tumors in pediatric cancer patients (18 years or younger). The successful applications will add to -the newly established Cancer Adoptive Cellular Therapy (Can-ACT) Network, dedicated to developing innovative cell therapy approaches for the treatment of solid tumors in pediatric and adult tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.
Funding Opportunity PAR-23-318 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. Applicants are required to propose partnerships between at least one U.S. institution and one LMIC institution.
Funding Opportunity RFA-DA-25-023 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) aims to support research programs that adopt innovative scalable technologies to inventory, register and molecularly profile distributed cell ensembles encoding the effects of addictive substances, across various stages of exposure (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches capable of integrating data generated through population-scale measurements of cellular activity dynamics in behaving rodents, with other granular data modalities, collected from the same cells at single-cell resolution, such as transcriptomic class, epigenetic state, connectivity and spatial localization. The overarching goal is to deliver reference multimodal datasets thatwillinform new descriptive and predictive models of how neuronal ensembles encode addiction-associated neurobehavioral states.
Notice NOT-CA-24-018 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-25-140 from the NIH Guide for Grants and Contracts. This initiative would solicit research to target gaps in our knowledge about how best to address the mental health needs of YLWH in low- and middle-income countries in ways that are easy to scale up. There are two main goals of the initiative. The first is to increase the number of mental health interventions that are tailored to the unique needs of adolescents living with HIV, both in terms of their developmental needs as well as the issues they have to attend to as a result of living with a chronic, stigmatized disease. The second goal is to ensure that interventions are streamlined so that they can be implemented in resource-limited settings.
Notice NOT-CA-24-016 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-081 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications to usethe NIH INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) to access resources to generate a large volume of integrated genomic and multi-omics data to facilitate discovery of the molecular mechanisms of health conditions related to Down syndrome. These data, and associated clinical and phenotypic data, will become part of the INCLUDE Project data resource for sharing with the research community. No funding will be provided directly to applicants under this NOFO. Applicants are encouraged to propose omics essays of existing biospecimens collected from individuals with Down syndrome and controls. The program will accept applications that propose whole genome sequencing, including both short-read and long-read, exome, epigenome, and transcriptome sequencing, as well as proteomic, metabolomic, and single-cell RNA sequencing and ATAC sequencing, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing collections. The omics data and related phenotypic data will be deposited in a public INCLUDE Project controlled-access database.
Notice NOT-NS-24-016 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-049 from the NIH Guide for Grants and Contracts
Notice NOT-ES-24-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-24-093 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to advance system-level approaches to improve patient safety by improving healthcare worker safety and well-being. Patient safety cannot be fully achieved without healthcare worker safety and well-being. This NOFO will contribute to AHRQs goal of reinvigorating the patient safety movement by adding fresh perspectives and insights of healthcare professionals to efforts to improve patient safety.
Notice NOT-OD-24-032 from the NIH Guide for Grants and Contracts
Notice NOT-NS-24-029 from the NIH Guide for Grants and Contracts
Notice NOT-NR-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-099 from the NIH Guide for Grants and Contracts
Notice NOT-DC-24-008 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-066 from the NIH Guide for Grants and Contracts. The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Funding Opportunity RFA-TR-24-001 from the NIH Guide for Grants and Contracts. NCATS seeks to facilitate rare diseases research by enabling efficient and effective movement toward clinical trials in multiple rare diseases. The purpose of this NOFO is to provide support for basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease, and in the process to identify and overcome challenges in adapting the oncology basket trial model to rare diseases. Projects proposed for this NOFO will require individuals with expertise in carrying out clinical trials in rare diseases. Applicants are expected to collaborate with clinical investigators at academic institutions. Projects involving clinical investigators who are part of the Rare Disease Clinical Research Network (RDCRN) and which focus on diseases under study in the RDCRN are strongly encouraged. See https://www.rarediseasesnetwork.org/ for additional information.